SGRY

Weak July jobs data raises hopes for Fed easing, putting health care and select retail ETFs and stocks in focus.

Surgery Partners, Inc. (SGRY) Q2 2026 Earnings Call Transcript

Surgery Partners NASDAQ: SGRY reported second-quarter 2026 revenue and adjusted EBITDA above its internal expectations, while reaffirming its full-year outlook ahead of the anticipated sale of its Idaho Falls market operations to Intermountain Health.

Surgery Partners (SGRY) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.17 per share a year ago.

Surgery Partners (SGRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Surgery Partners, Inc. (NASDAQ:SGRY) stock is trading higher on Friday as the company announced a significant transaction involving the sale of its ownership interests in Idaho Falls facilities to Intermountain Health.

BRENTWOOD, Tenn., July 24, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced it, along with its existing partner Intermountain Health, has placed into escrow signature pages to definitive agreements, pursuant to which Surgery Partners would sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health.

Surgery Partners (SGRY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Surgery Partners (SGRY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

The average of price targets set by Wall Street analysts indicates a potential upside of 26.1% in Surgery Partners (SGRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.